Compare Mesoblast Limited (MESO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Virgin Galactic Holdings, Inc. — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Virgin Galactic Holdings, Inc. trades at $2.96 (market cap $456.30M). The key difference: Mesoblast Limited is far larger — about 3.8× Virgin Galactic Holdings, Inc.'s market cap, and Mesoblast Limited is more actively traded (239,027 versus 4,518,834). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| MESO | SPCE | |
|---|---|---|
Market Cap | $1.75B | $456.30M |
Volume | 239,027 | 4,518,834 |
Sector | Health | Industrials |
52-Week High | $20.96 | $7.52 |
52-Week Low | $13.19 | $2.17 |
Typical Hold Time | 14 Days | 69 Days |
Enterprise Value | $1.83B | $420.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting persistent operational losses and a bearish technical outlook. The company continues to burn cash with negative gross and net profit margins, though recent earnings beats and strong ticket demand for future spaceflights offer a glimmer of hope. Cash flow trends show a gradual improvement, with a projected positive net cash flow of $25 million in 2026.
The outlook remains high-risk, high-reward. The path to profitability hinges on the successful commercial launch of Delta flights in 2027. While analyst sentiment is mixed and significant dilution and debt are concerns, the company's unique position in commercial spaceflight presents a speculative opportunity for investors with a long-term horizon and high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
